RVNC - レバンス・セラピュ―ティクス (Revance Therapeutics Inc.) レバンス・セラピュ―ティクス

 RVNCのチャート


 RVNCの企業情報

symbol RVNC
会社名 Revance Therapeutics Inc (レバンス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レバンス・セラピューティクス(Revance Therapeutics Inc.)は臨床段階のバイオテクノロジー会社である。同社は美容及び治療的適応症のためのボツリヌス毒素製品の開発、製造及び商業化に従事する。同社のペプチド技術は、注射用ダキシボトリュームトキシンA(RT002)または注射可能RT002及びダキシボチュリントキシンA局所用ゲル(RT001)またはRT001注射剤という2つの治験薬品候補を通じてA型ボツリヌス毒素を送達する。同社はRT002注射剤の臨床開発に従事する。RT002注射剤は生理食塩水ベースの製剤中でボツリヌス毒素 - ペプチド複合体を利用する。RT002注射剤はペプチドは標的筋肉の細胞外構造及び細胞表面受容体と相互作用する。この相互作用は毒素分子を標的部位に制限し、隣接筋肉への広がりを減少させる。同社はグラベラ・ライン、頸部ジストニア及び足底筋膜炎の治療のためのRT002の開発を行う。   レバンス・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。審美及び治療応用のためのボツリヌス毒素製品の開発、製造、商業化に従事。主要製品候補の「RT001」は、独自の技術による注射の必要のないゲルタイプのボツリヌス毒素製品。また、注射タイプの「RT002」は、ボツリヌス毒素の深い浸透により、より長い持続効果が期待される。   Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
本社所在地 7555 Gateway Boulevard Newark CA 94560 USA
代表者氏名 Angus Charles Russell アンガス・チャールズ・ラッセル
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-742-3400
設立年月日 36373
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 134人
url www.revance.com
nasdaq_url https://www.nasdaq.com/symbol/rvnc
adr_tso
EBITDA EBITDA(百万ドル) -132.59800
終値(lastsale) 23.57
時価総額(marketcap) 870626090.87
時価総額 時価総額(百万ドル) 884.66250
売上高 売上高(百万ドル) 0.99100
企業価値(EV) 企業価値(EV)(百万ドル) 650.92850
当期純利益 当期純利益(百万ドル) -135.67500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Revance Therapeutics Inc revenues increased from $150K to $879K. Net loss increased 28% to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling and Adminstative balance increase of 75% to $21.8M (expense) Research_Development balance increase of 18% to $41.3M (expense).

 RVNCのテクニカル分析


 RVNCのニュース

   Revance Therapeutics’ (RVNC) “Buy” Rating Reiterated at Mizuho  2019/11/07 23:02:46 Modern Readers
Revance Therapeutics (NASDAQ:RVNC)‘s stock had its “buy” rating reaffirmed by equities research analysts at Mizuho in a note issued to investors on Tuesday, AnalystRatings.com reports. They presently have a $34.00 target price on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 119.50% from the company’s current price. A number of […]
   Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management  2019/10/30 17:09:40 Benzinga
Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC ) named Mark Foley as its new CEO. The addition of a commercial-focused CEO, with experience in unlocking shareholder value in aesthetics, is a “major positive,” according to Wells Fargo. The Analyst Wells Fargo’s Jacob Hughes upgraded Revance Therapeutics from Market Perform to Outperform raising the price target from $12.50 to $20. The Thesis Mark Foley’s strong track record of commercial success in aesthetics is particularly important, as Revance Therapeutics is transitioning from a development stage to commercialization, Hughes said in the upgrade note. He … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know  2019/07/25 14:33:51 Zacks Investment Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   4 biotechs that could be the next takeout targets after AbbVie's $63 billion acquisition of Allergan  2019/06/26 18:45:00 Business Insider
AbbVie's recent deal for the pharmaceutical company Allergan is the latest in a string of healthcare M&A this year that has shifted the pharmaceutical industry's landscape. AbbVie is betting on Allergan's cosmetic products, like Botox, and other medical areas like women's health, neuroscience, eye care, and more. Analysts at Stifel say four biotechs could also be the next takeover targets: Revance Therapeutics, TherapeuticsMD, Aerie Pharmaceuticals, and Kala Pharmaceuticals. Click here for more BI Prime stories. US drugmaker AbbVie just announced a mega-deal to buy pharmaceutical company Allergan for about $63 billion. It's only the latest in a string of active healthcare deals this year , with Bristol-Myers Squibb's $74 billion proposed acquisition of Celgene and Eli Lilly's $8 billion agreement to buy the biotech Loxo Oncology in January. With Tuesday's deal, AbbVie is betting on Allergan cosmetic products like the well-known filler Botox and fat-freezing procedure CoolSculpting. But the drugmaker also clearly values Allergan's other medical treatments in areas like women's health, neuroscience, eye care and more, noted Stifel analysts Annabel Samimy and Nick Runibo. "This demonstration of interest could bring a host of other transactions that complement and build on franchises that [AbbVie] appears more committed to than [Allergan] has been," they said.
   Revance Therapeutics’ (RVNC) “Buy” Rating Reiterated at Mizuho  2019/11/07 23:02:46 Modern Readers
Revance Therapeutics (NASDAQ:RVNC)‘s stock had its “buy” rating reaffirmed by equities research analysts at Mizuho in a note issued to investors on Tuesday, AnalystRatings.com reports. They presently have a $34.00 target price on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 119.50% from the company’s current price. A number of […]
   Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management  2019/10/30 17:09:40 Benzinga
Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC ) named Mark Foley as its new CEO. The addition of a commercial-focused CEO, with experience in unlocking shareholder value in aesthetics, is a “major positive,” according to Wells Fargo. The Analyst Wells Fargo’s Jacob Hughes upgraded Revance Therapeutics from Market Perform to Outperform raising the price target from $12.50 to $20. The Thesis Mark Foley’s strong track record of commercial success in aesthetics is particularly important, as Revance Therapeutics is transitioning from a development stage to commercialization, Hughes said in the upgrade note. He … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know  2019/07/25 14:33:51 Zacks Investment Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   4 biotechs that could be the next takeout targets after AbbVie's $63 billion acquisition of Allergan  2019/06/26 18:45:00 Business Insider
AbbVie's recent deal for the pharmaceutical company Allergan is the latest in a string of healthcare M&A this year that has shifted the pharmaceutical industry's landscape. AbbVie is betting on Allergan's cosmetic products, like Botox, and other medical areas like women's health, neuroscience, eye care, and more. Analysts at Stifel say four biotechs could also be the next takeover targets: Revance Therapeutics, TherapeuticsMD, Aerie Pharmaceuticals, and Kala Pharmaceuticals. Click here for more BI Prime stories. US drugmaker AbbVie just announced a mega-deal to buy pharmaceutical company Allergan for about $63 billion. It's only the latest in a string of active healthcare deals this year , with Bristol-Myers Squibb's $74 billion proposed acquisition of Celgene and Eli Lilly's $8 billion agreement to buy the biotech Loxo Oncology in January. With Tuesday's deal, AbbVie is betting on Allergan cosmetic products like the well-known filler Botox and fat-freezing procedure CoolSculpting. But the drugmaker also clearly values Allergan's other medical treatments in areas like women's health, neuroscience, eye care and more, noted Stifel analysts Annabel Samimy and Nick Runibo. "This demonstration of interest could bring a host of other transactions that complement and build on franchises that [AbbVie] appears more committed to than [Allergan] has been," they said.
   Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference  2019-05-14 Business Wire
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Healthcare Conference in New York, NY. …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レバンス・セラピュ―ティクス RVNC Revance Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)